New models for pharmaceutical innovation in low-income countries.
作者信息
Ardal Christine, Iversen Johanne Helene, Myhr Kirsten
机构信息
Global Health Unit, Norwegian Knowledge Centre for Health Services, Norway.
出版信息
Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.
PMID:22016131
Abstract
摘要
相似文献
1
New models for pharmaceutical innovation in low-income countries.
Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.
2
Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14.
3
The role of academic institutions in the development of drugs for rare and neglected diseases.
Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4.
4
A new era of hope for the world's most neglected diseases.
PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8.
5
The European rare diseases therapeutic initiative.
PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.
6
Uncommon ventures launch to tackle uncommon diseases.
Nat Med. 2013 Aug;19(8):950-1. doi: 10.1038/nm0813-950.
7
Jumpstarting research into neglected diseases.
Cell. 2006 Nov 3;127(3):443-5. doi: 10.1016/j.cell.2006.10.022.
8
PPPs succeeding in tackling neglected diseases.
Nat Rev Drug Discov. 2005 Oct;4(10):796-7. doi: 10.1038/nrd1868.
9
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
Drug Discov Today. 2013 Nov;18(21-22):1043-51. doi: 10.1016/j.drudis.2013.08.006. Epub 2013 Aug 19.
10
In silico repositioning of approved drugs for rare and neglected diseases.
Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1.
Zotero 插件